# US 2012/0252730 A1 · Platelet aggregation inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252730 A1
- Document ID: US20120252730A1
- Status: Published application
- Kind: A1
- Application number: 13/393,608
- Filed: 2010-09-02
- Published: 2012-10-04
- Earliest claimed: 2009-09-03
- Assignees: The University of Chicago
- Inventors: Milan Mrksich; Juan Sanchez-Cortes
- Web page: https://patentgrep.com/patent/US20120252730A1

## CPC

- C07K 7/56: the cyclisation not occurring through 2,4-diamino-butanoic acid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/75: Fibrinogen
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are disclosed.

## Claims

### Claim 1

A compound of formula I, II, III, IV, or V:
wherein
represents a bond;
X1 and X5 are independently selected residues capable of forming a bond between X1 and X5 to obtain a cyclic compound;
X2 is absent or is a sequence of independently selected amino acids that is from one to six amino acids in length;
X4 is absent or is a sequence of independently selected amino acids that is from one to six amino acids in length;
wherein the sum of the length of amino acids in X2 plus X4 is from zero to 6 amino acids;
X3 is a hydrophobic amino acid residue; and
G* is glycyl or sarcosyl;
Y1 is absent, H, acetyl, or an amino protecting group;
Y2 is —OH, NH2, or a carboxyl protecting group;
wherein one or more peptide linkages of Formulas I-V may optionally be replaced by a linkage selected from the group consisting of —CH2NH—, —CH2S—, CH2CH2—, —CH═CH— (cis and trans), —COCH2—, —CH(OH)CH2— and —CH2SO—;
or a pharmaceutically acceptable salt thereof;
with the proviso that the following peptides are excluded from the scope of formula (I):
(SEQ ID NO: 1)
HHLGGAKQAGDV,
(SEQ ID NO: 3)
LGGAKQAGDV,
and
(SEQ ID NO: 10)
LQAGDV.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X2 does not contain a Q.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X2 does not contain a K or R.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X2 does not contain a Q, K, or R.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X3 is G, A, V, I, or L.

### Claim 6 (depends on 1)

The compound of claim 1, wherein the compound is of formula I, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound of claim 1, wherein the compound is of formula II, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein represents —C(O)—O—, —C(O)—NH—, —NH—C(O)—, —S—
where Z1 and Z2 are independently selected —(CH2)n— groups, wherein n is an integer from 1 to 7, and wherein if n is an integer from 3 to 7, then one or two non-adjacent CH2 groups may be replaced with groups independently selected from the group consisting of: —C(O)—, —NH—, —N(CH3)—, —C(O)—NH—, —S—, —C(O)—O—, and —O—.

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein G* is glycine.

### Claim 10 (depends on 1)

The compound of claim 1, wherein said compound is selected from the group consisting of:
GAGDS (SEQ ID NO: 72);
GVGDS (SEQ ID NO: 73);
GIGDS (SEQ ID NO: 74); and
GLGDS (SEQ ID NO: 75); or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of formula II, X1 is mercaptopropionyl (Mpr) and Y1 is absent.

### Claim 12 (depends on 8)

The compound of claim 8, or a pharmaceutically acceptable salt thereof,
wherein represents a disulfide bond,
wherein X1 and X5 are independently selected from the group consisting of Mpr (mercaptopropionyl), Mvl (mercaptovaleryl), Cys, Pen (Penicillamine), Pmp (β1,β-pentamethylene-β-mercaptopropionic acid), and Pmc (amino-β1,β-pentamethylene-B-mercaptopropionic acid).

### Claim 13 (depends on 12)

The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein X1 is mercaptopropionyl (Mpr), X5 is Cys, and Y1 is absent.

### Claim 14 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Y2 is NH2.

### Claim 15 (depends on 1)

The compound of claim 1, wherein G* is Glycine.

### Claim 16 (depends on 5)

The compound of claim 5, wherein said compound is
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising:
a compound of claim 1, or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier

### Claim 18 (depends on 1)

A method of treating a platelet associated ischemic disorder in a patient comprising administering to said patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A method of treating platelet loss during extracorporeal circulation of blood comprising contacting said blood with a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 1)

A method of treating platelet aggregation, embolization or consumption of extracorporeal circulation comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 1)

A method for inhibiting platelet aggregation in a mammal comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 1)

A method for inhibiting clot formation in a mammal comprising administering an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 1)

A method for treating myocardial infarction in a mammal comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 1)

A method for treating stroke in a mammal comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 1)

A method for treating patients with acute coronary syndrome comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.
